The BioPharm Brief: Setbacks, Submissions, and a $1.3B Deal

Sep 03, 08:04 PM
Headliner
Share
Subscribe

Today’s BioPharm Brief leads with a late-stage clinical setback for Ultragenyx, a major gene therapy filing from uniQure, and a billion-dollar oncology licensing deal between HUTCHMED and GSK.

Share
Subscribe
Next
The BioPharm Brief: HER2 Approvals, Deals, and Survival Data
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief